pembrolizumabRecent, repeatedEvidence- NCT07749586 · Arvinas Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
- NCT07565285 · Primmune Therapeutics, Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Apr 2026
- NCT07751042 · Strand Therapeutics Inc. · Phase 2 · live · background · “KEYTRUDA®” · registered Apr 2026
- NCT07287917 · Aminex Therapeutics, Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Nov 2025
- NCT06984328 · Genmab · Phase 2 · background · “Pembrolizumab” · registered May 2025
| Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015) | 1921 studies | 2123 studies | comparator 10 · background 32 |
NivolumabRecent, repeatedEvidence- NCT07815574 · Scancell Ltd · Phase 3 · live · background · “Nivolumab & Ipilimumab” · registered Sep 2026
- NCT06640530 · Biocad · Phase 3 · live · comparator · “Opdivo” · registered Oct 2024
- NCT06587451 · Sandoz · Phase 3 · comparator · “Opdivo-EU (Induction)” · registered Aug 2024
- NCT06581406 · Replimune Inc. · Phase 3 · live · background · “Nivolumab” · registered Aug 2024
- NCT06362369 · 7 Hills Pharma, LLC · Phase 2 · live · background · “Nivolumab” · registered Mar 2024
| Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015) | 1517 studies | 1516 studies | comparator 10 · background 27 |
IpilimumabRecent, repeatedEvidence- NCT07815574 · Scancell Ltd · Phase 3 · live · background · “Nivolumab & Ipilimumab” · registered Sep 2026
- NCT06784648 · BioInvent International AB · Phase 2 · live · background · “Ipilimumab (YervoyTM, 50 mg/10 mL solution)” · registered Dec 2024
- NCT06587451 · Sandoz · Phase 3 · background · “Yervoy-EU (Induction)” · registered Aug 2024
- NCT06581406 · Replimune Inc. · Phase 3 · live · comparator · “Ipilimumab” · registered Aug 2024
- NCT06362369 · 7 Hills Pharma, LLC · Phase 2 · live · background · “Ipilimumab” · registered Mar 2024
| Bristol-Myers Squibb91% of its industry studiesUS: Bristol-Myers Squibb (FDA 2011)EU: Bristol-Myers Squibb (EMA 2011) | 88 studies | 66 studies | comparator 6 · background 22 |
PaclitaxelRecent, repeatedEvidence- NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Paclitaxel” · registered Mar 2026
- NCT07310784 · Suzhou BlueHorse Therapeutics Co., Ltd. · Phase 2 · live · comparator · “Dacarbazine, temozolomide, paclitaxel, carboplatin/cisplatin” · registered Dec 2025
- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Paclitaxel” · registered Aug 2023
- NCT05824975 · GI Innovation, Inc. · Phase 2 · live · background · “paclitaxel” · registered Mar 2023
- NCT04752826 · BioInvent International AB · Phase 2 · live · background · “Paclitaxel 80 mg/m2 weekly” · registered Dec 2020
| Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed | 44 studies | 77 studies | background 8 · comparator 5 |
TemozolomideRecent, repeatedEvidence- NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Temozolomide” · registered Mar 2026
- NCT07310784 · Suzhou BlueHorse Therapeutics Co., Ltd. · Phase 2 · live · comparator · “Dacarbazine, temozolomide, paclitaxel, carboplatin/cisplatin” · registered Dec 2025
- NCT06346067 · Erasca, Inc. · Phase 3 · live · comparator · “Temozolomide” · registered Mar 2024
- NCT05647954 · Taizhou Hanzhong biomedical co. LTD · Phase 3 · live · comparator · “Temozolomide + TACE” · registered Nov 2022
- NCT04478279 · Sapience Therapeutics · Phase 2 · live · background · “Temozolomide” · registered Jul 2020
| Merck & Co., Inc23% of its industry studiesUS: off-patent, 7 generics marketedEU: off-patent, 4 generics authorized | 44 studies | 55 studies | background 5 · comparator 7 |
CarboplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Carboplatin” · registered Mar 2026
- NCT07310784 · Suzhou BlueHorse Therapeutics Co., Ltd. · Phase 2 · live · comparator · “Dacarbazine, temozolomide, paclitaxel, carboplatin/cisplatin” · registered Dec 2025
- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Carboplatin” · registered Aug 2023
- NCT04993677 · Pfizer · Phase 2 · background · “carboplatin” · registered Jul 2021
- NCT04083599 · Genmab · Phase 2 · live · background · “Carboplatin” · registered Sep 2019
| Eli Lilly and Company16% of its industry studies | 33 studies | 44 studies | background 6 · comparator 3 |
DacarbazineRecent, repeatedPhase 4 trial recordedEvidence- NCT07310784 · Suzhou BlueHorse Therapeutics Co., Ltd. · Phase 2 · live · comparator · “Dacarbazine, temozolomide, paclitaxel, carboplatin/cisplatin” · registered Dec 2025
- NCT06346067 · Erasca, Inc. · Phase 3 · live · comparator · “Dacarbazine” · registered Mar 2024
- NCT05987332 · IDEAYA Biosciences · Phase 3 · live · comparator · “Dacarbazine” · registered Jul 2023
- NCT04200040 · OrienGene Biotechnology Ltd. · Phase 2 · comparator · “Dacarbazine (DTIC)” · registered Dec 2019
- NCT03070392 · Immunocore Ltd · Phase 2 · comparator · “Dacarbazine” · registered Feb 2017
| Bristol-Myers Squibb21% of its industry studies | 33 studies | 33 studies | comparator 22 · background 9 |
relatlimabRecent, repeatedPhase 4 trial recordedEvidence- NCT06246916 · Regeneron Pharmaceuticals · Phase 3 · live · comparator · “relatlimab+nivolumab” · registered Jan 2024
- NCT06264180 · Replimune Inc. · Phase 3 · live · comparator · “Nivolumab + Relatlimab” · registered Jan 2024
- NCT06112314 · Immunocore Ltd · Phase 3 · live · comparator · “Nivolumab + Relatlimab” · registered Oct 2023
| Bristol-Myers Squibb100% of its industry studies | 33 studies | 33 studies | comparator 3 |
toripalimabRecent, repeatedEvidence- NCT07099430 · Nanjing Leads Biolabs Co.,Ltd · Phase 2 · live · background · “Toripalimab Injection” · registered Jul 2025
- NCT05955105 · Innolake Biopharm · Phase 2 · live · background · “Toripalimab” · registered Jul 2023
- NCT05723432 · Shanghai Kanda Biotechnology Co., Ltd. · Phase 2 · live · background · “Toripalimab” · registered Feb 2023
| RemeGen Co., Ltd.15% of its industry studiesUS: Coherus Biosciences, Inc. (FDA 2023)EU: Topalliance Biosciences Europe Limited (EMA 2024) | 33 studies | 33 studies | background 3 |
PemetrexedRecent, repeatedEvidence- NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Pemetrexed” · registered Mar 2026
- NCT05180799 · BioAtla, Inc. · Phase 2 · live · background · “Pemetrexed (Alimta)” · registered Dec 2021
- NCT04993677 · Pfizer · Phase 2 · background · “pemetrexed” · registered Jul 2021
- NCT04198766 · Inhibrx Biosciences, Inc · Phase 2 · live · background · “Pemetrexed 500 mg/m2” · registered Dec 2019
- NCT04083599 · Genmab · Phase 2 · live · background · “Pemetrexed” · registered Sep 2019
| Eli Lilly and Company67% of its industry studiesUS: off-patent, 4 generics marketedEU: off-patent, 3 generics authorized | 22 studies | 44 studies | background 6 |
CisplatinRecent, repeatedEvidence- NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Cisplatin” · registered Mar 2026
- NCT07310784 · Suzhou BlueHorse Therapeutics Co., Ltd. · Phase 2 · live · comparator · “Dacarbazine, temozolomide, paclitaxel, carboplatin/cisplatin” · registered Dec 2025
- NCT04198766 · Inhibrx Biosciences, Inc · Phase 2 · live · background · “Cisplatin 75mg/m2” · registered Dec 2019
- NCT04083599 · Genmab · Phase 2 · live · background · “Cisplatin” · registered Sep 2019
- NCT03645928 · Iovance Biotherapeutics, Inc. · Phase 2 · background · “Cisplatin” · registered Aug 2018
| Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed | 22 studies | 44 studies | background 6 · comparator 1 |
BevacizumabRecent, repeatedEvidence- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Bevacizumab” · registered Aug 2023
- NCT05824975 · GI Innovation, Inc. · Phase 2 · live · background · “bevacizumab” · registered Mar 2023
- NCT03167177 · ImmunityBio, Inc. · Phase 2 · background · “Bevacizumab” · registered May 2017
| Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others | 22 studies | 22 studies | background 3 |
trametinibRecent, repeatedEvidence- NCT06346067 · Erasca, Inc. · Phase 3 · live · background · “Trametinib” · registered Mar 2024
- NCT05275374 · Xynomic Pharmaceuticals, Inc. · Phase 2 · live · background · “Trametinib” · registered Feb 2022
- NCT02967692 · Novartis · Phase 3 · background · “Trametinib” · registered Nov 2016
- NCT01072175 · Novartis · Phase 2 · background · “GSK1120212” · registered Feb 2010
| GlaxoSmithKline49% of its industry studiesEU: Novartis (EMA 2014) | 22 studies | 22 studies | background 4 |
cemiplimabRecent, repeatedEvidence- NCT06090266 · OncoResponse, Inc. · Phase 2 · live · background · “Cemiplimab” · registered Sep 2023
- NCT05259696 · Palleon Pharmaceuticals, Inc. · Phase 2 · background · “Cemiplimab” · registered Feb 2022
- NCT05094804 · OncoResponse, Inc. · Phase 2 · live · background · “Cemiplimab” · registered Sep 2021
- NCT04913220 · Sanofi · Phase 2 · background · “Cemiplimab” · registered May 2021
- NCT03684785 · Exicure, Inc. · Phase 2 · background · “Cemiplimab” · registered Sep 2018
| Regeneron Pharmaceuticals83% of its industry studiesUS: Regeneron Pharmaceuticals (FDA 2018)EU: Regeneron Pharmaceuticals (EMA 2019) | 22 studies | 12 studies | background 5 |
enzalutamideRecent, repeatedEvidence- NCT05914116 · DualityBio Inc. · Phase 2 · live · background · “Enzalutamide” · registered Jun 2023
- NCT05551117 · MacroGenics · Phase 2 · comparator · “Enzalutamide” · registered Sep 2022
| Astellas Pharma Inc45% of its industry studiesUS: Astellas Pharma Inc (FDA 2012)EU: off-patent, 1 generic authorized | 22 studies | 11 study | background 1 · comparator 1 |
Abiraterone AcetateRecent, repeatedEvidence- NCT05914116 · DualityBio Inc. · Phase 2 · live · background · “Abiraterone” · registered Jun 2023
- NCT05551117 · MacroGenics · Phase 2 · comparator · “Abiraterone” · registered Sep 2022
| Johnson & Johnson65% of its industry studiesUS: off-patent, 11 generics marketedEU: off-patent, 2 generics authorized | 22 studies | 11 study | background 1 · comparator 1 |